HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use Sensipar safely and effectively. See full prescribing information for Sensipar.

Sensipar® (cinacalcet) Tablets
Initial US Approval: 2004

RECENT MAJOR CHANGES
- Indications and Usage: Primary Hyperparathyroidism: 02/2011
- Dosage and Administration: Parathyroid Carcinoma / Primary Hyperparathyroidism: 02/2011
- Contraindications: Hypocalcemia: 02/2011

INDICATIONS AND USAGE
Sensipar is a calcium-sensing receptor agonist indicated for:
- Secondary Hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis: 2004
- Hypercalcemia in patients with Parathyroid Carcinoma (PC): 2004
- Severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy: 2004

DOSE AND ADMINISTRATION
For all indications, Sensipar should be taken with food or shortly after a meal and should always be taken whole and not divided.
- Secondary HPT in patients with CKD on dialysis: Administer starting dose is 30 mg twice daily.
- Titrating dose: Administer no more frequently than every 2 to 4 weeks through sequential doses of 30, 60, 90, 120, and 180 mg once daily as necessary to achieve target intact parathyroid hormone (iPTH) levels.
- iPTH levels: Should be measured no earlier than 12 hours after most recent dose.
- Hypercalcemia in patients with PC or severe hypercalcemia in patients with primary HPT: Administer starting dose is 30 mg twice daily.
- Titrating dose: Administer 2 to 4 times daily as necessary to achieve or normalize serum calcium levels.

DOSE FORMS AND STRENGTHS
Tablets: 30, 60, and 90 mg tablets (3)

FULL PRESCRIBING INFORMATION: CONTENTS*
1 INDICATIONS AND USAGE
1.1 Secondary Hyperparathyroidism
1.2 Parathyroid Carcinoma
1.3 Primary Hyperparathyroidism
2 DOSE AND ADMINISTRATION
2.1 Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis
2.2 Parathyroid Carcinoma and Primary Hyperparathyroidism
3 DOSE FORMS AND STRENGTHS
4 CONTRAINDICATIONS
5 WARNINGS AND PRECAUTIONS
5.1 Hypocalcemia
5.2 Seizures
5.3 Hypotension and/or Worsening Heart Failure
5.4 Adynamic Bone Disease
5.5 Hepatic Impairment
5.6 Laboratory Tests
6 ADVERSE REACTIONS
6.1 Clinical Trials Experience
6.2 Postmarketing Experience with Sensipar
7 DRUG INTERACTIONS
7.1 Strong CYP3A4 Inhibitors
7.2 CYP2D6 Substrates
8 USE IN SPECIFIC POPULATIONS
8.1 Pregnancy: Category C
8.2 Nursing Mothers
8.3 Pediatric Use
8.4 Geriatric Use
8.5 Renal Impairment
8.6 Hepatic Impairment
10 OVERDOSAGE
11 DESCRIPTION
12 CLINICAL PHARMACOLOGY
12.1 Mechanism of Action
12.2 Pharmacodynamics
12.3 Pharmacokinetics
13 NONCLINICAL TOXICOLOGY
14 CLINICAL STUDIES
14.1 Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis
14.2 Parathyroid Carcinoma
14.3 Patients with Severe Hypercalcemia Due to Primary Hyperparathyroidism
16 HOW SUPPLIED/STORAGE AND HANDLING
17 PATIENT COUNSELING INFORMATION

*Sections or subsections omitted from the full prescribing information are not listed.
FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

1.1 Secondary Hyperparathyroidism

Sensipar is indicated for the treatment of secondary hyperparathyroidism (HPT) in patients with chronic kidney disease (CKD) on dialysis [see Clinical Studies (14.1)].

1.2 Parathyroid Carcinoma

Sensipar is indicated for the treatment of hypercalcemia in patients with parathyroid carcinoma [see Clinical Studies (14.2)].

1.3 Primary Hyperparathyroidism

Sensipar is indicated for the treatment of severe hypercalcemia in patients with primary HPT who are unable to undergo parathyroidectomy [see Clinical Studies (14.3)].

2 DOSAGE AND ADMINISTRATION

Sensipar tablets should be taken whole and should not be divided. Sensipar should be taken with food or shortly after a meal.

Dosage must be individualized.

2.1 Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

The recommended starting oral dose of Sensipar is 30 mg once daily. Serum calcium and serum phosphorus should be measured within 1 week and intact parathyroid hormone (iPTH) should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar. Sensipar should be titrated no more frequently than every 2 to 4 weeks through sequential doses of 30, 60, 90, 120, and 180 mg once daily to target iPTH levels of 150 to 300 pg/mL. Serum iPTH levels should be assessed no earlier than 12 hours after dosing with Sensipar.

Sensipar can be used alone or in combination with vitamin D sterols and/or phosphate binders.

During dose titration, serum calcium levels should be monitored frequently and if levels decrease below the normal range, appropriate steps should be taken to increase serum calcium levels, such as by providing supplemental calcium, initiating or increasing the dose of calcium-based phosphate binder, initiating or increasing the dose of vitamin D sterols, or temporarily withholding treatment with Sensipar [see Warnings and Precautions (5.1, 5.6)].

2.2 Parathyroid Carcinoma and Primary Hyperparathyroidism

The recommended starting oral dose of Sensipar is 30 mg twice daily.

The dose of Sensipar should be titrated every 2 to 4 weeks through sequential doses of 30 mg twice daily, 60 mg twice daily, and 90 mg twice daily, and 90 mg 3 or 4 times daily as necessary to normalize serum calcium levels [see Warnings and Precautions (5.6)].

3 DOSAGE FORMS AND STRENGTHS

Sensipar tablets are formulated as light-green, film-coated, oval-shaped tablets marked with “AMG” on one side and “30” or “60” or “90” on the opposite side of the 30 mg, 60 mg, or 90 mg strengths, respectively.

Reference ID: 2910153
4 CONTRAINDICATIONS

Hypocalcemia: Sensipar treatment should not be initiated if serum calcium is less than the lower limit of the normal range [see Warnings and Precautions (5.1)].

5 WARNINGS AND PRECAUTIONS

5.1 Hypocalcemia

Sensipar lowers serum calcium and, therefore, patients should be carefully monitored for the occurrence of hypocalcemia. Potential manifestations of hypocalcemia include paresthesias, myalgias, muscle cramping, tetany, and convulsions.

Serum calcium should be measured within 1 week after initiation or dose adjustment of Sensipar. Once the maintenance dose has been established, serum calcium should be measured approximately monthly [see Dosage and Administration (2.1)].

If serum calcium falls below 8.4 mg/dL but remains above 7.5 mg/dL, or if symptoms of hypocalcemia occur, calcium-containing phosphate binders and/or vitamin D sterols can be used to raise serum calcium. If serum calcium falls below 7.5 mg/dL, or if symptoms of hypocalcemia persist and the dose of vitamin D cannot be increased, withhold administration of Sensipar until serum calcium levels reach 8.0 mg/dL and/or symptoms of hypocalcemia have resolved. Treatment should be reinitiated using the next lowest dose of Sensipar [see Dosage and Administration (2.1)].

In 26-week studies of patients with CKD on dialysis, 66% of patients receiving Sensipar compared with 25% of patients receiving placebo developed at least one serum calcium value < 8.4 mg/dL. Less than 1% of patients in each group permanently discontinued study drug due to hypocalcemia.

Sensipar is not indicated for patients with CKD not on dialysis. In patients with secondary HPT and CKD not on dialysis, the long-term safety and efficacy of Sensipar have not been established. Clinical studies indicate that Sensipar-treated patients with CKD not on dialysis have an increased risk for hypocalcemia compared with Sensipar-treated patients with CKD on dialysis, which may be due to lower baseline calcium levels. In a phase 3 study of 32 weeks duration and including 404 patients with CKD not on dialysis (302 cinacalcet, 102 placebo), in which the median dose for cinacalcet was 60 mg per day at the completion of the study, 80% of Sensipar treated patients experienced at least one serum calcium value < 8.4 mg/dL compared with 5% of patients receiving placebo.

5.2 Seizures

In three clinical studies of patients with CKD on dialysis, 5% of the patients in both the Sensipar and placebo groups reported a history of seizure disorder at baseline. During the studies, seizures (primarily generalized or tonic-clonic) were observed in 1.4% (9/656) of Sensipar treated patients and 0.4% (2/470) of placebo-treated patients. Five of the nine Sensipar-treated patients had a history of a seizure disorder and two were receiving anti-seizure medication at the time of their seizure. Both placebo-treated patients had a history of seizure disorder and were receiving antiseizure medication at the time of their seizure. While the basis for the reported difference in seizure rate is not clear, the threshold for seizures is lowered by significant reductions in serum calcium levels. Therefore, serum calcium levels should be closely monitored in patients receiving Sensipar, particularly in patients with a history of a seizure disorder [see Warnings and Precautions (5.1)].

5.3 Hypotension and/or Worsening Heart Failure

In postmarketing safety surveillance, isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia have been reported in patients with impaired cardiac function, in which a causal relationship to Sensipar could not be completely excluded and which may be mediated by reductions in serum calcium levels [see Adverse Reactions(6.2)].
5.4 Adynamic Bone Disease

Adynamic bone disease may develop if iPTH levels are suppressed below 100 pg/mL. One clinical study evaluated bone histomorphometry in patients treated with Sensipar for 1 year. Three patients with mild hyperparathyroid bone disease at the beginning of the study developed adynamic bone disease during treatment with Sensipar. Two of these patients had iPTH levels below 100 pg/mL at multiple time points during the study. In three 6-month, phase 3 studies conducted in patients with CKD on dialysis, 11% of patients treated with Sensipar had mean iPTH values below 100 pg/mL during the efficacy-assessment phase. If iPTH levels decrease below 150 pg/mL in patients treated with Sensipar, the dose of Sensipar and/or vitamin D sterols should be reduced or therapy discontinued.

5.5 Hepatic Impairment

Cinacalcet exposure, as defined by the Area Under the Curve (AUC0-Inf), is increased by 2.4 and 4.2 fold in patients with moderate and severe hepatic impairment, respectively. These patients should be monitored throughout treatment with Sensipar [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].

5.6 Laboratory Tests

Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

Serum calcium and serum phosphorus should be measured within 1 week and iPTH should be measured 1 to 4 weeks after initiation or dose adjustment of Sensipar. Once the maintenance dose has been established, serum calcium and serum phosphorus should be measured approximately monthly, and iPTH every 1 to 3 months [see Dosage and Administration (2.1)]. Measurements of PTH during the Sensipar studies were obtained using the Nichols iPTH immunoradiometric assay (IRMA).

In patients with end-stage renal disease, testosterone levels are often below the normal range. In a placebo-controlled study in patients with CKD on dialysis, there were reductions in total and free testosterone in male patients following 6 months of treatment with Sensipar. Levels of total testosterone decreased by a median of 15.8% in the Sensipar-treated patients and by 0.6% in the placebo-treated patients. Levels of free testosterone decreased by a median of 31.3% in the Sensipar-treated patients and by 16.3% in the placebo-treated patients. The clinical significance of these reductions in serum testosterone is unknown.

Patients with Parathyroid Carcinoma or Primary Hyperparathyroidism

Serum calcium should be measured within 1 week after initiation or dose adjustment of Sensipar. Once maintenance dose levels have been established, serum calcium should be measured every 2 months [see Dosage and Administration (2.2)].

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

In three double-blind, placebo-controlled clinical trials, 1126 patients with CKD on dialysis received study drug (656 Sensipar, 470 placebo) for up to 6 months. The most frequently reported adverse reactions (incidence of at least 5% in the Sensipar group and greater than placebo) are provided in Table 1. The most frequently reported adverse reactions in the Sensipar group were nausea, vomiting, and diarrhea.
Table 1. Adverse Reaction Incidence (≥ 5%) in Patients on Dialysis

<table>
<thead>
<tr>
<th>Event*</th>
<th>Placebo (n = 470)</th>
<th>Sensipar (n = 656)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(%)</td>
<td>(%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>19</td>
<td>31</td>
</tr>
<tr>
<td>Vomiting</td>
<td>15</td>
<td>27</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>20</td>
<td>21</td>
</tr>
<tr>
<td>Myalgia</td>
<td>14</td>
<td>15</td>
</tr>
<tr>
<td>Dizziness</td>
<td>8</td>
<td>10</td>
</tr>
<tr>
<td>Hypertension</td>
<td>5</td>
<td>7</td>
</tr>
<tr>
<td>Asthenia</td>
<td>4</td>
<td>7</td>
</tr>
<tr>
<td>Anorexia</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Pain Chest, Non-Cardiac</td>
<td>4</td>
<td>6</td>
</tr>
<tr>
<td>Access Infection</td>
<td>4</td>
<td>5</td>
</tr>
</tbody>
</table>

*Included are events that were reported at a greater incidence in the Sensipar group than in the placebo group.

The incidence of serious adverse reactions was similar in the Sensipar and placebo groups (29% vs. 31%, respectively).

12-Month Experience with Sensipar in Secondary Hyperparathyroidism

Two hundred sixty-six patients from two of the phase 3 studies in patients with CKD on dialysis continued to receive Sensipar or placebo treatment in a 6-month, double-blind extension study (12-month total treatment duration). The incidence and nature of adverse reactions in this long term extension study were comparable to those observed in the original phase 3 studies.

Parathyroid Carcinoma and Primary Hyperparathyroidism

The safety profile of Sensipar in these patient populations is generally consistent with that seen in patients with CKD on dialysis. Forty six patients were treated with cinacalcet in a single arm study, 29 with Parathyroid Carcinoma and 17 with intractable PHPT. Nine (20%) of the patients withdrew from the study due to adverse events. The most frequent adverse reactions and the most frequent cause of withdrawal in these patient populations were nausea and vomiting. Severe or prolonged cases of nausea and vomiting can lead to dehydration and worsening hypercalcemia so careful monitoring of electrolytes is recommended in patients with these symptoms.

Eight patients died while on study, 7 with parathyroid carcinoma (24%) and 1 (6%) with intractable PHPT. Causes of death were cardiovascular (5 patients), multi-organ failure (1 patient), gastrointestinal hemorrhage (1 patient) and metastatic carcinoma (1 patient). Adverse events of hypocalcemia were reported in three patients (7%).
Table 2. Adverse Reactions Occurring in ≥10% of Total Subjects

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Parathyroid Carcinoma (N=29)</th>
<th>Intractable pHPT (N=17)</th>
<th>Total (N=46)</th>
<th>n (%)</th>
<th>n (%)</th>
<th>n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Subjects Reporting Adverse Events</td>
<td>28 (97)</td>
<td>17 (100)</td>
<td>45 (98)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nausea</td>
<td>19 (66)</td>
<td>10 (59)</td>
<td>29 (63)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vomiting</td>
<td>15 (52)</td>
<td>6 (35)</td>
<td>21 (46)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paresthesia</td>
<td>4 (14)</td>
<td>5 (29)</td>
<td>9 (20)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fatigue</td>
<td>6 (21)</td>
<td>2 (12)</td>
<td>8 (17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fracture</td>
<td>6 (21)</td>
<td>2 (12)</td>
<td>8 (17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>6 (21)</td>
<td>2 (12)</td>
<td>8 (17)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anorexia</td>
<td>6 (21)</td>
<td>1 (6)</td>
<td>7 (15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Astenia</td>
<td>5 (17)</td>
<td>2 (12)</td>
<td>7 (15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dehydration</td>
<td>7 (24)</td>
<td>0 (0)</td>
<td>7 (15)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anemia</td>
<td>5 (17)</td>
<td>1 (6)</td>
<td>6 (13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Arthralgia</td>
<td>5 (17)</td>
<td>1 (6)</td>
<td>6 (13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Constipation</td>
<td>3 (10)</td>
<td>3 (18)</td>
<td>6 (13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Depression</td>
<td>3 (10)</td>
<td>3 (18)</td>
<td>6 (13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Headache</td>
<td>6 (21)</td>
<td>0 (0)</td>
<td>6 (13)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infection Upper Respiratory</td>
<td>3 (10)</td>
<td>2 (12)</td>
<td>5 (11)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pain Limb</td>
<td>3 (10)</td>
<td>2 (12)</td>
<td>5 (11)</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

N=Number of subjects receiving at least one dose of study drug.

6.2 Postmarketing Experience with Sensipar

The following adverse reactions have been identified during postapproval use of Sensipar. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Rash, hypersensitivity reactions (including angioedema and urticaria), diarrhea, and myalgia have been identified as adverse reactions during postapproval use of Sensipar. Isolated, idiosyncratic cases of hypotension, worsening heart failure, and/or arrhythmia have been reported in Sensipar-treated patients with impaired cardiac function in postmarketing safety surveillance.

7 DRUG INTERACTIONS

7.1 Strong CYP3A4 Inhibitors

Cinacalcet is partially metabolized by CYP3A4. Dose adjustment of Sensipar may be required if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., ketoconazole, itraconazole). The iPTH and serum calcium concentrations should be closely monitored in these patients [see Clinical Pharmacology (12.3)].
7.2 CYP2D6 Substrates

Cinacalcet is a strong inhibitor of CYP2D6. Dose adjustments may be required for concomitant medications that are predominantly metabolized by CYP2D6 (e.g., desipramine, metoprolol, and carvedilol) and particularly those with a narrow therapeutic index (e.g., flecainide and most tricyclic antidepressants) [see Clinical Pharmacology (12.3)].

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy: Category C

In pregnant female rats given oral gavage doses of 2, 25, 50 mg/kg/day cinacalcet during gestation, no teratogenicity was observed at doses up to 50 mg/kg/day (exposure 4 times those resulting with a human oral dose of 180 mg/day based on area under the curve [AUC] comparison). Decreased fetal body weights were observed at all doses (less than 1 to 4 times a human oral dose of 180 mg/day based on AUC comparison) in conjunction with maternal toxicity (decreased food consumption and body weight gain).

In pregnant female rabbits given oral gavage doses of 2, 12, 25 mg/kg/day cinacalcet during gestation, no adverse fetal effects were observed (exposures less than with a human oral dose of 180 mg/day based on AUC comparisons). Reductions in maternal food consumption and body weight gain were seen at doses of 12 and 25 mg/kg/day. Sensipar has been shown to cross the placental barrier in rabbits.

In pregnant rats given oral gavage doses of 5, 15, 25 mg/kg/day cinacalcet during gestation through lactation, no adverse fetal or pup (post-weaning) effects were observed at 5 mg/kg/day (exposures less than with a human therapeutic dose of 180 mg/day based on AUC comparisons). Higher doses of 15 and 25 mg/kg/day cinacalcet (exposures 2 to 3 times a human oral dose of 180 mg/day based on AUC comparisons) were accompanied by maternal signs of hypocalcemia (periparturient mortality and early postnatal pup loss), and reductions in postnatal maternal and pup body-weight gain.

There are no adequate and well-controlled studies of Sensipar in pregnant women. Sensipar should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Women who become pregnant during Sensipar treatment are encouraged to enroll in Amgen’s Pregnancy Surveillance Program. Patients or their physicians should call 1-800-772-6436 (1-800-77-AMGEN) to enroll.

8.3 Nursing Mothers

Studies in rats have shown that Sensipar is excreted in the milk with a high milk-to-plasma ratio. It is not known whether this drug is excreted in human milk. Considering these data in rats, and because many drugs are excreted in human milk and there is a potential for clinically significant adverse reactions in infants who ingest Sensipar, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the lactating woman.

8.4 Pediatric Use

The safety and efficacy of Sensipar in pediatric patients have not been established.

8.5 Geriatric Use

Of the 1136 patients enrolled in the Sensipar phase 3 clinical program in patients with CKD on dialysis, 26% were ≥ 65 years old, and 9% were ≥ 75 years old. No differences in the safety and efficacy of Sensipar were observed in patients greater or less than 65 years of age. No dosage adjustment is required for geriatric patients [see Clinical Pharmacology (12.3)].
8.6 Renal Impairment

No dosage adjustment is necessary for renal impairment [see Clinical Pharmacology (12.3)].

8.7 Hepatic Impairment

Patients with moderate and severe hepatic impairment should have serum calcium, serum phosphorus, and iPTH levels monitored closely throughout treatment with Sensipar because cinacalcet exposure (AUC\textsubscript{0-inf}) is increased by 2.4 and 4.2 fold, respectively, in these patients [see Warnings and Precautions (5.5) and Clinical Pharmacology (12.3)].

10 OVERDOSAGE

Doses titrated up to 300 mg once daily have been safely administered to patients on dialysis. Overdosage of Sensipar may lead to hypocalcemia. In the event of overdosage, patients should be monitored for signs and symptoms of hypocalcemia and appropriate measures taken to correct serum calcium levels [see Warnings and Precautions (5.1)].

Since Sensipar is highly protein bound, hemodialysis is not an effective treatment for overdosage of Sensipar.

11 DESCRIPTION

Sensipar (cinacalcet) is a calcimimetic agent that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium. Sensipar tablets contain the hydrochloride salt of cinacalcet. Its empirical formula is C\textsubscript{23}H\textsubscript{23}F\textsubscript{3}N\cdot HCl with a molecular weight of 393.9 g/mol (hydrochloride salt) and 357.4 g/mol (free base). It has one chiral center having an R-absolute configuration. The R-enantiomer is the more potent enantiomer and has been shown to be responsible for pharmacodynamic activity.

The hydrochloride salt of cinacalcet is a white to off-white, crystalline solid that is soluble in methanol or 95% ethanol and slightly soluble in water.

Sensipar tablets are formulated as light-green, film-coated, oval-shaped tablets for oral administration in strengths of 30 mg, 60 mg, and 90 mg of cinacalcet as the free base equivalent (33 mg, 66 mg, and 99 mg as the hydrochloride salt, respectively).

The hydrochloride salt of cinacalcet is described chemically as N-[1-(R)-(-)-(1-naphthyl)ethyl]-3-[3-(trifluoromethyl)phenyl]-1-aminopropane hydrochloride and has the following structural formula:

![Structural formula of cinacalcet hydrochloride](image)

**Inactive Ingredients**

The following are the inactive ingredients in Sensipar tablets: pre-gelatinized starch, microcrystalline cellulose, povidone, crospovidone, colloidal silicon dioxide and magnesium stearate. Tablets are coated with color (Opadry® II green), clear film coat (Opadry® clear), and carnauba wax.

Reference ID: 2910153
12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Secondary HPT in patients with CKD is a progressive disease, associated with increases in PTH levels and derangements in calcium and phosphorus metabolism. Increased PTH stimulates osteoclastic activity resulting in cortical bone resorption and marrow fibrosis. The goals of treatment of secondary HPT are to lower the levels of PTH, calcium, and phosphorus in the blood in order to prevent progressive bone disease and the systemic consequences of disordered mineral metabolism. Reductions in PTH are associated with a decrease in bone turnover and bone fibrosis in patients with CKD on dialysis and uncontrolled secondary HPT.

The calcium-sensing receptor on the surface of the chief cell of the parathyroid gland is the principal regulator of PTH synthesis and secretion. Sensipar directly lowers PTH levels by increasing the sensitivity of the calcium-sensing receptor to extracellular calcium. The reduction in PTH is associated with a concomitant decrease in serum calcium levels. Measurements of PTH during the Sensipar studies were obtained using the Nichols iPTH immunoradiometric assay.

12.2 Pharmacodynamics

Reduction in iPTH levels correlated with the plasma cinacalcet concentrations in patients with CKD. The nadir in iPTH level occurs approximately 2 to 6 hours postdose, corresponding with the maximum plasma concentration (C_{max}) of cinacalcet. After steady-state cinacalcet concentrations are reached (which occurs within 7 days of dose change), serum calcium concentrations remain constant over the dosing interval in patients with CKD.

12.3 Pharmacokinetics

Absorption and Distribution

After oral administration of cinacalcet, C_{max} is achieved in approximately 2 to 6 hours. Cinacalcet C_{max} and AUC_{(0\rightarrow\infty)} were increased by 82% and 68%, respectively, following administration with a high-fat meal compared with fasting in healthy volunteers. The C_{max} and AUC_{(0\rightarrow\infty)} of cinacalcet were increased by 65% and 50%, respectively, when cinacalcet was administered with a low-fat meal compared with fasting.

After absorption, cinacalcet concentrations decline in a biphasic fashion with a terminal half-life of 30 to 40 hours. Steady-state drug levels are achieved within 7 days, and the mean accumulation ratio is approximately 2 with once-daily oral administration. The median accumulation ratio is approximately 2 to 5 with twice-daily oral administration. The AUC and C_{max} of cinacalcet increase proportionally over the dose range of 30 to 180 mg once daily. The volume of distribution is approximately 1000 L, indicating extensive distribution. Cinacalcet is approximately 93% to 97% bound to plasma protein(s). The ratio of blood cinacalcet concentration to plasma cinacalcet concentration is 0.80 at a blood cinacalcet concentration of 10 ng/mL.

Metabolism and Excretion

Cinacalcet is metabolized by multiple enzymes, primarily CYP3A4, CYP2D6, and CYP1A2. After administration of a 75 mg radiolabeled dose to healthy volunteers, cinacalcet was metabolized via: 1) oxidative N-dealkylation to hydrocinnamic acid and hydroxy-hydrocinnamic acid, which are further metabolized via β-oxidation and glycine conjugation; the oxidative N-dealkylation process also generates metabolites that contain the naphthalene ring; and 2) oxidation of the naphthalene ring on the parent drug forming dihydrodiols, which are further conjugated with glucuronic acid. The plasma concentrations of the major circulating metabolites, including the cinnamic acid derivatives and glucuronidated dihydrodiols, markedly exceed the parent drug concentrations. The hydrocinnamic acid metabolite and glucuronide conjugates have minimal or no calcimimetic activity. Renal excretion of metabolites was the primary route of elimination of radioactivity. Approximately 80% of the dose was recovered in the urine and 15% in the feces.
Drug Interactions
In vitro studies indicate that cinacalcet is a strong inhibitor of CYP2D6, but not an inhibitor of CYP1A2, CYP2C9, CYP2C19, and CYP3A4. In vitro induction studies indicate that cinacalcet is not an inducer of CYP450 enzymes. Tables 3 and 4 list the findings from in vivo drug-drug interaction studies.

Table 3. Effect of co-administered drugs on cinacalcet

<table>
<thead>
<tr>
<th>Coadministered drug and dosing</th>
<th>Cinacalcet</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Dose*</td>
</tr>
<tr>
<td></td>
<td></td>
</tr>
<tr>
<td>200 mg ketoconazole twice daily for 7 days</td>
<td>90 mg on day 5</td>
</tr>
<tr>
<td>1500 mg calcium carbonate, single dose</td>
<td>100 mg</td>
</tr>
<tr>
<td>80 mg pantoprazole daily for 3 days</td>
<td>90 mg on day 3</td>
</tr>
<tr>
<td>2400 mg sevelamer HCl three times a day for 2 days</td>
<td>90 mg on day 1 with first dose of sevelamer</td>
</tr>
</tbody>
</table>

*Single dose

Table 4. Effect of cinacalcet co-administration on other drugs

<table>
<thead>
<tr>
<th>Cinacalcet dosing regimen</th>
<th>Coadministered drug</th>
<th>Name and Dose</th>
<th>Mean change in AUC$_{0-\infty}$</th>
<th>Mean change in Cmax</th>
</tr>
</thead>
<tbody>
<tr>
<td>30 mg twice daily for 8 days</td>
<td>25 mg warfarin* tablet†</td>
<td>↑1 % for R-warfarin</td>
<td>↓10 % for R-warfarin</td>
<td></td>
</tr>
<tr>
<td>90 mg daily for 7 days to CYP2D6 extensive metabolizers</td>
<td>50 mg desipramine‡</td>
<td>↑264%</td>
<td>↑75%</td>
<td></td>
</tr>
<tr>
<td>90 mg daily for 5 days</td>
<td>2 mg midazolam‡</td>
<td>↑5%</td>
<td>↓5%</td>
<td></td>
</tr>
<tr>
<td>25 or 100 mg single dose to CYP2D6 extensive metabolizers</td>
<td>50 mg amitriptyline‡ single dose</td>
<td>↑21-22% for amitriptyline</td>
<td>↑11-15% for nor triptyline‡</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>↑17-23% for nor triptyline‡</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*No significant change in prothrombin time
†Single dose on day 5
‡Nortriptyline is an active metabolite of amitriptyline

Hepatic Impairment
The disposition of a 50 mg Sensipar single dose was compared between patients with hepatic impairment and patients with normal hepatic function. Cinacalcet exposure (AUC$_{0-\infty}$) was comparable between healthy volunteers and patients with mild hepatic impairment. However, in patients with moderate and severe hepatic impairment (as indicated by the Child-Pugh method), cinacalcet exposures (AUC$_{0-\infty}$) were 2.4 and 4.2 fold higher, respectively, than that in healthy volunteers. The mean half-life of cinacalcet increased from 49 hours in healthy volunteers to 65 hours and 84 hours in patients with moderate and severe hepatic impairment, respectively. Protein binding of cinacalcet is not affected by impaired hepatic function [see Warnings and Precautions (5.5) and Use in Specific Populations (8.7)].

Renal Impairment
The pharmacokinetic profile of a 75 mg Sensipar single dose in patients with mild, moderate, and severe renal impairment, and those on hemodialysis or peritoneal dialysis is comparable with that in healthy volunteers [see Use in Specific Populations (8.6)].
Geriatric Patients
The pharmacokinetic profile of cinacalcet in geriatric patients (age $\geq$ 65 years, n = 12) is similar to that for patients who are < 65 years of age (n = 268) [see Use in Specific Populations (8.5)].

Pediatric Patients
The pharmacokinetics of cinacalcet has not been studied in patients < 18 years of age [see Use in Specific Populations (8.4)].

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

Carcinogenicity
Standard lifetime dietary carcinogenicity bioassays were conducted in mice and rats. Mice were given cinacalcet at dietary doses of 15, 50, and 125 mg/kg/day in males and 30, 70, and 200 mg/kg/day in females (exposures up to 2 times those resulting with a human oral dose of 180 mg/day based on AUC comparison). Rats were given dietary doses of 5, 15, and 35 mg/kg/day in males and 5, 20, 3, and 5 mg/kg/day in females (exposures up to 2 times those resulting with a human oral dose of 180 mg/day based on AUC comparison). No increased incidence of tumors was observed following treatment with cinacalcet.

Mutagenicity
Cinacalcet was not genotoxic in the Ames bacterial mutagenicity assay, nor in the Chinese Hamster Ovary (CHO) cell HGPRT forward mutation assay and CHO cell chromosomal aberration assay, with and without metabolic activation, nor in the in vivo mouse micronucleus assay.

Impairment of Fertility
Female rats were given oral gavage doses of 5, 25, and 75 mg/kg/day cinacalcet beginning 2 weeks before mating and continuing through gestation day 7. Male rats were given oral doses 4 weeks prior to mating, during mating (3 weeks) and 2 weeks postmating. No effects were observed in male or female fertility at 5 and 25 mg/kg/day (exposures up to 3 times those resulting with a human oral dose of 180 mg/day based on AUC comparison). At 75 mg/kg/day, there were slight adverse effects (slight decreases in body weight and food consumption) in males and females.

14 CLINICAL STUDIES

14.1 Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease on Dialysis

Three 6-month, multicenter, randomized, double-blind, placebo-controlled clinical studies of similar design were conducted in patients with CKD on dialysis. A total of 665 patients were randomized to Sensipar and 471 patients to placebo. The mean age of the patients was 54 years, 62% were male, and 52% were Caucasian. The average baseline iPTH level by the Nichols intact immunoradiometric assay (IRMA) was 712 pg/mL, with 26% of the patients having a baseline iPTH level $\geq$ 800 pg/mL. The mean baseline Ca x P ion product was 61 mg$^2$/dL$^2$. The average duration of dialysis prior to study enrollment was 67 months. Ninety-six percent of patients were on hemodialysis and 4% on peritoneal dialysis. At study entry, 66% of the patients were receiving vitamin D sterols and 93% were receiving phosphate binders. Sensipar (or placebo) was initiated at a dose of 30 mg once daily and titrated every 3 or 4 weeks to a maximum dose of 180 mg once daily to achieve an iPTH of $\leq$ 250 pg/mL. The dose was not increased if a patient had any of the following: iPTH $\leq$ 200 pg/mL, serum calcium $< 7.8$ mg/dL, or any symptoms of hypocalcemia. If a patient experienced symptoms of hypocalcemia or had a serum calcium $< 8.4$ mg/dL, calcium supplements and/or calcium-based phosphate binders could be increased. If these measures were insufficient, the vitamin D dose could be increased. Approximately 70% of patients in the Sensipar arm and 80% of the patients in the placebo arm completed the 6-month studies. In the primary efficacy analysis, 40% of the patients on Sensipar and 5% of placebo-treated patients achieved an iPTH $\leq$ 250 pg/mL (p < 0.001) (Table 5, Figure 1). These studies showed that Sensipar reduced iPTH while lowering Ca x P, calcium, and phosphorus levels (Table 5, Figure 2). The median dose of Sensipar at the completion of the studies was 90 mg. Patients with milder disease typically required lower doses.
Similar results were observed when either the iPTH or biointact PTH (biPTH) assay was used to measure PTH levels in CKD patients on dialysis; treatment with cinacalcet did not alter the relationship between iPTH and biPTH.
Table 5. Effects of Sensipar on iPTH, Ca x P, Serum Calcium, and Serum Phosphorus in 6-month Phase 3 Studies (Patients on Dialysis)

<table>
<thead>
<tr>
<th></th>
<th>Study 1 Placebo (n = 205)</th>
<th>Study 1 Sensipar (n = 205)</th>
<th>Study 2 Placebo (n = 165)</th>
<th>Study 2 Sensipar (n = 166)</th>
<th>Study 3 Placebo (n = 101)</th>
<th>Study 3 Sensipar (n = 294)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>iPTH</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (pg/mL):</td>
<td>535</td>
<td>537</td>
<td>556</td>
<td>547</td>
<td>670</td>
<td>703</td>
</tr>
<tr>
<td>Mean (SD)</td>
<td>651 (398)</td>
<td>636 (341)</td>
<td>630 (317)</td>
<td>652 (372)</td>
<td>832 (486)</td>
<td>848 (685)</td>
</tr>
<tr>
<td>Evaluation Phase (pg/mL)</td>
<td>563</td>
<td>275</td>
<td>592</td>
<td>238</td>
<td>737</td>
<td>339</td>
</tr>
<tr>
<td>Median Percent Change</td>
<td>+3.8</td>
<td>-48.3</td>
<td>+8.4</td>
<td>-54.1</td>
<td>+2.3</td>
<td>-48.2</td>
</tr>
<tr>
<td>Patients Achieving Primary Endpoint (iPTH ≤ 250 pg/mL) (%)²</td>
<td>4%</td>
<td>41%**</td>
<td>7%</td>
<td>46%**</td>
<td>6%</td>
<td>35%**</td>
</tr>
<tr>
<td>Patients Achieving ≥ 30% Reduction in iPTH (%)²</td>
<td>11%</td>
<td>61%</td>
<td>12%</td>
<td>68%</td>
<td>10%</td>
<td>59%</td>
</tr>
<tr>
<td>Patients Achieving iPTH ≤ 250 pg/mL and Ca x P &lt; 55 mg²/dL² (%)</td>
<td>1%</td>
<td>32%</td>
<td>5%</td>
<td>35%</td>
<td>5%</td>
<td>28%</td>
</tr>
<tr>
<td><strong>Ca x P</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mg²/dL²)</td>
<td>62</td>
<td>61</td>
<td>61</td>
<td>61</td>
<td>61</td>
<td>59</td>
</tr>
<tr>
<td>Evaluation Phase (mg²/dL²)</td>
<td>59</td>
<td>52</td>
<td>59</td>
<td>47</td>
<td>57</td>
<td>48</td>
</tr>
<tr>
<td>Median Percent Change</td>
<td>-2.0</td>
<td>-14.9</td>
<td>-3.1</td>
<td>-19.7</td>
<td>-4.8</td>
<td>-15.7</td>
</tr>
</tbody>
</table>

** p < 0.001 compared with placebo; p-values presented for primary endpoint only

¹ iPTH value based on averaging over the evaluation phase (defined as weeks 13 to 26 in studies 1 and 2, and weeks 17 to 26 in study 3)

Values shown are medians unless indicated otherwise.
Table 5. Effects of Sensipar on iPTH, Ca x P, Serum Calcium, and Serum Phosphorus in 6-month Phase 3 Studies (Patients on Dialysis) (continued)

<table>
<thead>
<tr>
<th>Study</th>
<th>Placebo</th>
<th>Sensipar</th>
<th>Placebo</th>
<th>Sensipar</th>
<th>Placebo</th>
<th>Sensipar</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>(n = 205)</td>
<td>(n = 205)</td>
<td>(n = 165)</td>
<td>(n = 166)</td>
<td>(n = 101)</td>
<td>(n = 294)</td>
</tr>
<tr>
<td>Calcium</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mg/dL)</td>
<td>9.8</td>
<td>9.9</td>
<td>9.9</td>
<td>10.0</td>
<td>9.9</td>
<td>9.8</td>
</tr>
<tr>
<td>Evaluation Phase (mg/dL)</td>
<td>9.9</td>
<td>9.1</td>
<td>9.1</td>
<td>9.1</td>
<td>10.0</td>
<td>9.1</td>
</tr>
<tr>
<td>Median Percent Change</td>
<td>+0.5</td>
<td>-5.5</td>
<td>+0.1</td>
<td>-7.4</td>
<td>+0.3</td>
<td>-6.0</td>
</tr>
<tr>
<td>Phosphorus</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Baseline (mg/dL)</td>
<td>6.3</td>
<td>6.1</td>
<td>6.1</td>
<td>6.0</td>
<td>6.1</td>
<td>6.0</td>
</tr>
<tr>
<td>Evaluation Phase (mg/dL)</td>
<td>6.0</td>
<td>5.6</td>
<td>5.9</td>
<td>5.1</td>
<td>5.6</td>
<td>5.3</td>
</tr>
<tr>
<td>Median Percent Change</td>
<td>-1.0</td>
<td>-9.0</td>
<td>-2.4</td>
<td>-12.4</td>
<td>-5.6</td>
<td>-8.6</td>
</tr>
</tbody>
</table>

** p < 0.001 compared with placebo; p-values presented for primary endpoint only

a iPTH value based on averaging over the evaluation phase (defined as weeks 13 to 26 in studies 1 and 2 and weeks 17 to 26 in study 3)

Values shown are medians unless indicated otherwise
Figure 1. Mean (SE) iPTH Values (Pooled Phase 3 Studies)

Data are presented for patients who completed the studies; Placebo (n = 342), Sensipar (n = 439).
Reductions in iPTH and Ca x P were maintained for up to 12 months of treatment.

Sensipar decreased iPTH and Ca x P levels regardless of disease severity (i.e., baseline iPTH value), duration of dialysis, and whether or not vitamin D sterols were administered. Approximately 60% of patients with mild (iPTH $\geq 300$ to $\leq 500$ pg/mL), 41% with moderate (iPTH $> 500$ to 800 pg/mL), and 11% with severe (iPTH $> 800$ pg/mL) secondary HPT achieved a mean iPTH value of $\leq 250$ pg/mL. Plasma iPTH levels were measured using the Nichols IRMA.

### 14.2 Parathyroid Carcinoma

Twenty-nine patients with parathyroid carcinoma were enrolled in a single-arm, open-label study. The study consisted of two phases, a dose-titration phase and a maintenance phase. Patients initially received 30 mg cinacalcet twice daily and then were titrated every 2 weeks to a maximum dose of 90 mg 4 times a day. Dosage escalation during the variable-length (2 to 16 weeks) titration phase continued until the serum calcium concentration was $\leq 10$ mg/dL (2.5 mmol/L), the patient reached the highest possible dosage, or adverse events precluded further dosage increases.

Twenty-nine patients entered the study. The median exposure to cinacalcet was 229 days (range: 1 to 1,051). At baseline the mean (SE) serum calcium was 14.1 (0.4) mg/dL. At the end of the titration phase the mean (SE) serum calcium was 12.4 (0.5) mg/dL, which is a mean reduction of 1.7 (0.6) mg/dL from baseline. Figure 3 illustrates mean serum calcium (mg/dL) over time for all patients still on study at each time point from the beginning of
titration to study visit week 80. Daily dose during the study ranged from 30 mg twice a day to 90 mg four times a day.

**Figure 3. Serum Calcium Values in Patients With Parathyroid Carcinoma Receiving Sensipar at Baseline, Titration, and Maintenance Phase**

![Graph showing serum calcium values over time](image)

n = Number of patients with non-missing values at the timepoint.
End of Titration (EOT) phase could occur at any visit from week 2 to 18. Patients at EOT are those who completed titration.

### 14.3 Patients with Severe Hypercalcemia Due to Primary Hyperparathyroidism

Seventeen patients with severe hypercalcemia due to primary HPT, who had failed or had contraindications to parathyroidectomy, participated in an open-label study. The study consisted of two phases, a dose-titration phase and a maintenance phase. In this trial severe hypercalcemia was defined as a screening serum calcium level of > 12.5 mg/dL. Patients initially received 30 mg cinacalcet twice daily and then were titrated every 2 weeks to a maximum dose of 90 mg 4 times a day. Dosage escalation during the variable-length (2 to 16 weeks) titration phase continued until the serum calcium concentration was ≤ 10 mg/dL (2.5 mmol/L), the patient reached the highest possible dosage, or adverse events precluded further dosage increases.

Seventeen patients entered the study. The median exposure to cinacalcet was 270 days (range: 32 to 1,105). At baseline the mean (SE) serum calcium was 12.7 (0.2) mg/dL. At the end of the titration phase the mean (SE) serum calcium was 10.4 (0.3) mg/dL, which is a mean reduction of 2.3 (0.3) mg/dL from baseline. Figure 4 illustrates mean serum calcium (mg/dL) over time for all patients still on study at each time point from the beginning of titration to study visit week 80. Daily dose during the study ranged from 30 mg twice a day to 90 mg four times a day.
Figure 4. Mean Serum Calcium (SE) at Baseline, End of Titration, and Scheduled Maintenance Visits (Patients with Severe intractable primary HPT)

Intractable pHPT (n):

B  EOT  8  16  24  32  40  48  56  64  72  80

-  17
-  14
-  14
-  13
-  12
-  11
-  10
-  9
-  8
-  7
-  6
-  5
-  4
-  3
-  3

n = Number of patients with non-missing values at the timepoint.
End of Titration (EOT) phase could occur at any visit from week 2 to 18. Patients at EOT are those who completed titration.

16 HOW SUPPLIED/STORAGE AND HANDLING

Sensipar 30 mg tablets are formulated as light-green, film-coated, oval-shaped tablets marked with “AMG” on one side and “30” on the opposite side, packaged in bottles of 30 tablets. (NDC 55513-073-30)

Sensipar 60 mg tablets are formulated as light-green, film-coated, oval-shaped tablets marked with “AMG” on one side and “60” on the opposite side, packaged in bottles of 30 tablets. (NDC 55513-074-30)

Sensipar 90 mg tablets are formulated as light-green, film-coated, oval-shaped tablets marked with “AMG” on one side and “90” on the opposite side, packaged in bottles of 30 tablets. (NDC 55513-075-30)

Storage
Store at 25°C (77°F); excursions permitted from 15°C to 30°C (59°F to 86°F). [See USP controlled room temperature].

17 PATIENT COUNSELING INFORMATION

- Take with food: Patients should be advised to take Sensipar with food or shortly after a meal. Tablets should be taken whole and should not be divided.

- Laboratory monitoring: Patients should be informed of the importance of regular blood tests, in order to monitor the safety and efficacy of Sensipar therapy.
- Side-Effects of Treatment: Patients should be advised to report nausea, vomiting, and potential symptoms of hypocalcemia, including tingling/numbness of the skin, muscle pain, and muscle cramping.

- Seizures: Patients should be queried if they are taking medication to prevent seizures or have had seizures in the past and be advised to report any seizure episodes while on Sensipar therapy.